Sangamo Therapeutics (NASDAQ:SGMO) Issues Quarterly Earnings Results

Sangamo Therapeutics (NASDAQ:SGMO) posted its quarterly earnings results on Monday. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.02), Zacks reports. Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. The firm had revenue of $7.55 million for the quarter, compared to the consensus estimate of $11.70 million.

Sangamo Therapeutics Stock Up 2.9 %

Shares of Sangamo Therapeutics stock opened at $1.01 on Tuesday. The company has a market capitalization of $210.73 million, a price-to-earnings ratio of -1.35 and a beta of 1.49. Sangamo Therapeutics has a 12-month low of $0.30 and a 12-month high of $3.18. The firm’s 50-day moving average price is $1.10 and its two-hundred day moving average price is $1.41.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of Sangamo Therapeutics in a research report on Monday, January 27th. StockNews.com lowered shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, December 24th. Jefferies Financial Group dropped their price objective on shares of Sangamo Therapeutics from $7.00 to $3.00 and set a “buy” rating on the stock in a research report on Tuesday, December 31st. Truist Financial dropped their price objective on shares of Sangamo Therapeutics from $7.00 to $5.00 and set a “buy” rating on the stock in a research report on Thursday, January 23rd. Finally, Wells Fargo & Company decreased their price target on shares of Sangamo Therapeutics from $3.00 to $2.00 and set an “equal weight” rating on the stock in a research note on Tuesday, December 31st. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $5.80.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.